| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1191: Nemolizumab for treating moderate to severe prurigo nodularis |
|
Medicine details |
|
| Medicine name | nemolizumab (Nemluvio®) |
| Formulation | Intravenous |
| Reference number | 4834 |
| Indication | Treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy |
| Company | Galderma UK Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/07/2026 |
| NICE guidance | TA1191: Nemolizumab for treating moderate to severe prurigo nodularis |